A detailed history of Redmile Group, LLC transactions in 89bio, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 1,745,656 shares of ETNB stock, worth $14.8 Million. This represents 0.91% of its overall portfolio holdings.

Number of Shares
1,745,656
Previous 2,264,566 22.91%
Holding current value
$14.8 Million
Previous $26.4 Million 46.96%
% of portfolio
0.91%
Previous 1.04%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$7.31 - $10.9 $3.79 Million - $5.66 Million
-518,910 Reduced 22.91%
1,745,656 $14 Million
Q1 2024

May 15, 2024

BUY
$8.13 - $13.77 $2.4 Million - $4.06 Million
295,164 Added 14.99%
2,264,566 $26.4 Million
Q4 2023

Feb 14, 2024

BUY
$6.66 - $16.03 $8.04 Million - $19.4 Million
1,207,447 Added 158.47%
1,969,402 $22 Million
Q2 2023

Aug 14, 2023

SELL
$14.15 - $22.03 $1.95 Million - $3.04 Million
-138,045 Reduced 15.34%
761,955 $14.4 Million
Q1 2023

May 15, 2023

BUY
$10.48 - $16.94 $9.43 Million - $15.2 Million
900,000 New
900,000 $13.7 Million

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $394M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.